Clinical trial NCT05656534: Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder
Official title: Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Alcohol Use Disorder
Keywords: suvorexant
alcohol use disorder
electromyography
functional magnetic resonance imaging
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2022-12-19
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this double-blind clinical trial is to further explore if, how, and for whom orexin antagonism modifies brain-behavior stress targets in moderate to severe alcohol use disorder (AUD). The main questions it aims to answer are:

* Does an acute dose of suvorexant (SUV) and/or daily use of SUV modify brain-behavior targets of AUD dysfunction?
* Does daily SUV use change alcohol behavior and if so, is this change in behavior linked to brain-behavior change?

Participants will be randomized to a treatment group (SUV or placebo) and protocol arm, electromyography (EMG) only or EMG+functional magnetic resonance imaging (fMRI). Participants will be asked to complete the following:

* Baseline lab visit(s) that include the psychophysiological stress paradigm (EMG only or EMG+fMRI, dependent upon randomization).
* Acute drug challenge where the participant will return to the lab to repeat the stress paradigm following administration of a single dose of either 10mg SUV or placebo.
* Medication trial where participants will be instructed to take 10mg capsules of SUV or placebo orally each night before bedtime for 4-weeks.
* Daily reports of medication adherence, side-effects, sleep, alcohol use, and mood will be collected via smartphones during the 4-week medication trial.
* Post-treatment lab visit(s) where participants will return to the lab at the end of the medication trial and complete the same stress paradigm from baseline (EMG only or EMG+fMRI, dependent upon randomization).


Eligibility criteria: Inclusion Criteria:

* Age 18-65.
* Participant is able to give informed consent.
* Generally medically and physically healthy as confirmed by medical history.
* Meet DSM-5 diagnostic criteria for current moderate or severe AUD.
* Engage in heavy alcohol use defined as drinking equal or greater than 14 standard drinks per week if male and equal or greater than 7 standard drinks per week if female.

Exclusion Criteria:

* Clinically significant medical or neurological condition (e.g., liver disease, narcolepsy, complex sleep behaviors, severe hepatic impairment, COPD, severe obstructive sleep apnea).
* Current cognitive dysfunction (traumatic brain injury, mental retardation, organic mental syndrome, pervasive developmental disorder, or dementia).
* Current use of antihistamines, strong or moderate inhibitors of CYP3A liver enzymes, strong CYP3A inducers, or digoxin.
* Current or past DSM-5 diagnosis of mania, schizophrenia, psychosis, suicidality, major depressive disorder, or obsessive compulsive disorder.
* Current substance use disorder other than alcohol or mild cannabis use disorder.
* Treatment seeking for AUD.
* Recent psychotropic medication use in the past 2 months.
* Currently smokes 5 or more cigarettes (or electronic equivalent) per day.
* BMI equal or greater than 35.
* Engage in night-shift work.
* Lack of fluency in English.
* Presence of ferrous-containing metal in the body.
* Inability to tolerate small, enclosed spaces.
* Deafness in one or both ears.
* Currently pregnant (positive pregnancy test), lactating, or not agreeing to use birth control methods during the duration of the trial.

Primary outcomes:
measure: Startle reactivity to stress with an acute dose of suvorexant.
timeFrame: Change from baseline to 2 hours post-ingestion of an acute dose of suvorexant.
measure: Startle reactivity to stress with daily use of suvorexant.
timeFrame: Change from baseline to post-treatment, up to 1.5-2 months.
measure: Alcohol behavior and daily use of suvorexant.
timeFrame: Change from baseline to post-treatment, up to 1.5-2 months.
Secondary outcomes:
measure: Brain change and daily use of suvorexant.
timeFrame: Change from baseline to post-treatment, up to 1.5-2 months.
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
Study officials:
References: